ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Merus tops Bicara
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
ASCO 2025 preview – patritumab hangs in the balance
Herthena-Lung02 data are an ASCO shocker.
ASCO 2025 preview – Itovebi strengthens its first-line claim
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Mersana faces the inevitable
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
